Practice

Infographic: Biosimilars in Oncology

July 30th 2017

By The Center for Biosimilars Staff

Biologic medications are an integral, crucial, and effective part of medical management for many life-threatening diseases and conditions, including cancer, but biosimilars are not without concerns.

Biosimilar Rheumatology Roundup: July

July 29th 2017

By Kelly Davio

July was a busy month for biosimilars targeting rheumatology indications; this month saw a product launch, developments in the legal realm, new clinical data, and prospective changes to Medicare reimbursement.

Industry Experts See Need for Greater Education, Deeper Discounts for Biosimilars

July 28th 2017

By Kelly Davio

On Thursday, the Oncology Business Review (OBR) hosted a panel discussion, “The Advent of Biosimilars in Oncology: Planning Proactively for Change.”

The Top 5 Biosimilars Articles for the Week of July 24

July 28th 2017

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 24, 2017.

Review Examines Immunogenicity Rates in Patients Taking Innovator Biologics, Biosimilars

July 28th 2017

By Jackie Syrop

The potential immunogenicity of biosimilar agents is an important consideration in the treatment decision-making process, and a new systematic review of immunogenicity associated with biological therapies in chronic inflammatory diseases explores the frequency of immunogenicity and its potential impact on efficacy and safety.

Awareness of Biosimilars High Among Irish Specialist Physicians, Pharmacists; Less So Among GPs

July 25th 2017

By Jackie Syrop

A new survey assessing awareness of and attitudes about biosimilars among medical specialists and pharmacists in Ireland found that majority of such experts say that they are familiar or very familiar with the term “biosimilar,” but many general practitioners (GPs) were either unable to define or had never heard the term.

Safety, Efficacy of Biosimilar Switching Not Established, Though Information Gap Narrows

July 21st 2017

By Jackie Syrop

An analysis of 53 switching studies reveals a variable level of good-quality evidence regarding switching from reference drugs to their biosimilars.

Pharmacists Grapple With the Nuances of the Biosimilars Regulatory Process

July 8th 2017

By The Center for Biosimilars Staff

This week, James Stevenson, PharmD, FASHP, professor at the University of Michigan College of Pharmacy, delivered a webinar via the Academy of Managed Care Pharmacy.

FDA: Expect Interchangeable Biosimilars Within 2 Years

July 4th 2017

By Jackie Syrop

An FDA official has said that the agency expects interchangeable biosimilars to come to market within 2 years and that the first interchangeable biosimilar will likely be reviewed by an FDA advisory committee of outside experts.

Review Suggests Interchangeability Nearing for Single Switch Between Infliximab and Its Biosimilar

June 30th 2017

By Jackie Syrop

Available data from comparative clinical trials and observational studies strongly confirm the equivalence between CT-P13 and originator infliximab for the treatment of rheumatologic diseases.